Immunotherapy (Checkpoint Inhibitor)

28 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Checkpoint Inhibitor) (16)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Pembrolizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pembrolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Nivolumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Adebrelimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Adebrelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Balstilimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Balstilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Camrelizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Camrelizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cemiplimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Cemiplimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Dostarlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Dostarlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Envafolimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Envafolimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Penpulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Penpulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Pucotenlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pucotenlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Retifanlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Serplulimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

Pembrolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Adebrelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Balstilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Camrelizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Cemiplimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Dostarlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Envafolimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Penpulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Pucotenlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Retifanlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Serplulimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

‹ 1 2 ›

Product Range

Company

Global Network

Immunotherapy (Checkpoint Inhibitor)

Immunotherapy (Checkpoint Inhibitor) (16)

Pembrolizumab

Nivolumab

Adebrelimab

Balstilimab

Camrelizumab

Cemiplimab

Dostarlimab

Envafolimab

Penpulimab

Pucotenlimab

Retifanlimab

Serplulimab

Pembrolizumab

Nivolumab

Adebrelimab

Balstilimab

Camrelizumab

Cemiplimab

Dostarlimab

Envafolimab

Penpulimab

Pucotenlimab

Retifanlimab

Serplulimab